Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2021
Pharma News, 2021
Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’
Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer’s therapy Aduhelm – but only if its assumptions on population size and uptake are different from...
Lilly to file for accelerated FDA approval of Alzheimer's drug after Aduhelm OK opens the floodgates
Eli Lilly plans to file for accelerated approval of its Alzheimer’s disease prospect donanemab later this year.
GSK’s drugs arm to get $11 bln windfall from consumer spin-off
June 23 (Businesshala) – GSK (GSK.
DeepMind uses AI to tackle neglected deadly diseases
Artificial intelligence is to be used to tackle the most deadly parasitic diseases in the developing world, tech company DeepMind has announced.
Moderna has renamed its coronavirus vaccine
The American company Moderna has changed the name of its coronavirus vaccine, it follows from the data of the European Medicines Agency (EMA).
Strand snags $52M to develop next-gen mRNA meds for cancer
For many, mRNA-based medicines are synonymous with COVID-19 vaccines, but vaccination is just the tip of the iceberg for the technology.
Novavax's COVID-19 shot won't see much U.S. use, but a big global market awaits: analyst
In rapidly developing a COVID-19 vaccine—and a highly effective one at that—Novavax got the hard part right.
Bristol Myers inks another Revlimid patent settlement—this time with Sun Pharma — as copycats near
As Bristol Myers Squibb looks to guard Celgene’s top-selling cancer drug Revlimid from copycat competition, the company has inked a series of deals to welcome generic challengers in waves.
J&J cell therapy partner Legend carves out production foothold in Belgium as myeloma drug nears finish line
As Legend Biotech and Johnson & Johnson's multiple myeloma cell therapy prospect nears the FDA finish line, the companies are moving to carve out a manufacturing foothold in Europe.
EU green lights AZ, MSD’s rare disease therapy Koselugo
The European Commission (EC) has granted AstraZeneca (AZ) and MSD’s Koselugo (selumetinib) a conditional approved for the treatment of children with symptomatic, inoperable p...
FDA Approves First Oral Blood Thinning Medication for Children
FDA Approves First Oral Blood Thinning Medication for ChildrenToday, the U.
U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug
WASHINGTON (Reuters) - The U.
35
36
37
38
39
40
41
42
43
